Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial
- 1 April 2002
- journal article
- clinical trial
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 32 (4) , 507-514
Abstract
Summary: Background Previous studies suggest that sublingual immunotherapy (SLIT) represents a safer alternative to injection immunotherapy but equivalent efficacy is yet to be confirmed.Objective To evaluate the efficacy and safety of SLIT in grass pollen‐induced seasonal rhinoconjunctivitis.Methods A randomized, placebo‐controlled trial in 56 adults over 18 months. Outcome measures included diary scores of seasonal symptoms and medication use, overall assessments, conjunctival and intradermal provocation tests and serum antibody measurements. To investigate possible mechanisms, sublingual biopsies were taken for measurement of local T cells, antigen‐presenting cells and IL‐12 mRNA expression.Results There were no significant differences between the immunotherapy (IT) and placebo groups for diary symptom scores (P = 0.48) or rescue medication (P = 0.19). The patients' overall assessment of hayfever severity compared with previous years showed a highly significant improvement in favour of the IT group (P < 0.02). After treatment the late skin response was smaller (P = 0.003) and the ratio of serum allergen‐specific IgG4/IgE was higher (P = 0.05) in the IT group. Both of these variables correlated with the clinical response to SLIT. There were no differences between groups in either the sublingual epithelium or lamina propria for numbers of CD3+ cells (epithelium: P = 0.9, lamina propria: P = 0.2), CD1a+ cells (P = 0.3, P = 0.25), CD68+ cells (P = 0.9, P = 1.0) or IL‐12 mRNA+ cells (P = 0.6, P = 0.4). Local side‐effects were minor and there were no serious treatment‐related adverse events.Conclusion Grass pollen sublingual immunotherapy was well tolerated. Although there was no significant change in diary scores, the improvement in overall assessments, which correlated with inhibition of the late skin response and increases in serum IgG4 : IgE ratio, indicates the need for larger, dose‐ranging studies.Keywords
This publication has 29 references indexed in Scilit:
- Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial☆☆☆★Journal of Allergy and Clinical Immunology, 1999
- Sublingual immunotherapy☆☆☆★Journal of Allergy and Clinical Immunology, 1999
- Sublingual‐swallow immunotherapy (SLIT) in patients with asthma due to house‐dust mites: a double‐blind, placebo‐controlled studyAllergy, 1999
- Sublingual immunotherapyClinical & Experimental Allergy, 1996
- A double‐blind, placebo‐controlled study of immunotherapy with grass‐pollen extract Alutard SQ during a 3–year period with initial rush immunotherapyAllergy, 1996
- A double‐blind, placebo‐controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extractAllergy, 1994
- The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 1989
- Regional variation in Langerhans cell distribution and density in normal human oral mucosa determined using monoclonal antibodies against CD1, HLADR, HLADQ and HLADPJournal of Oral Pathology & Medicine, 1989
- Magic lite design and developmentJournal of Bioluminescence and Chemiluminescence, 1989
- A double-blind histamine placebo—controlled trial of polymerized whole grass for immunotherapy of grass allergyJournal of Allergy and Clinical Immunology, 1983